Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2464858rdf:typepubmed:Citationlld:pubmed
pubmed-article:2464858lifeskim:mentionsumls-concept:C0020204lld:lifeskim
pubmed-article:2464858lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:2464858lifeskim:mentionsumls-concept:C0019740lld:lifeskim
pubmed-article:2464858lifeskim:mentionsumls-concept:C1511636lld:lifeskim
pubmed-article:2464858pubmed:issue5lld:pubmed
pubmed-article:2464858pubmed:dateCreated1989-3-16lld:pubmed
pubmed-article:2464858pubmed:abstractTextPBMC were isolated from a multiparous woman with HLA-B27 specific Abs in her serum. The HLA type of the donor was A2,9:B7. The PBMC were EBV transformed, and four cell lines making cytotoxic Abs to HLA-B27+ cells prepared. Hybridomas were constructed by fusing the EBV lines with the human fusion partner KR4. All four mAbs were of IgM isotype. One mAb (TrBH12) reacted specifically with B27+, B37+ and Bw47+ lymphoblastoid cell lines and with all B27+ PBMC except for a rare variant so far found only in one Norwegian family. Another mAb (Tr3B6) was cytotoxic for all B27+ cells tested, including the TrBH12- variant; in addition, it showed weaker cross-reactions to Bw42, B49 and a cell line with the probable phenotype B7,38. Supernatant from the Tr3B6 hybridoma was tested in lymphocytotoxicity against a panel of 658 individuals, 141 of whom were B27+. With this panel, Tr3B6 showed perfect correlation with HLA-B27. The two last mAbs (TrCG10 and TrBF1) reacted with all B27+ cells tested, but in addition showed quite extensive cross-reactions.lld:pubmed
pubmed-article:2464858pubmed:languageenglld:pubmed
pubmed-article:2464858pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2464858pubmed:citationSubsetIMlld:pubmed
pubmed-article:2464858pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2464858pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2464858pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2464858pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2464858pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2464858pubmed:statusMEDLINElld:pubmed
pubmed-article:2464858pubmed:monthNovlld:pubmed
pubmed-article:2464858pubmed:issn0001-2815lld:pubmed
pubmed-article:2464858pubmed:authorpubmed-author:HannestadKKlld:pubmed
pubmed-article:2464858pubmed:authorpubmed-author:BratlieAAlld:pubmed
pubmed-article:2464858pubmed:authorpubmed-author:HansenTTlld:pubmed
pubmed-article:2464858pubmed:issnTypePrintlld:pubmed
pubmed-article:2464858pubmed:volume32lld:pubmed
pubmed-article:2464858pubmed:ownerNLMlld:pubmed
pubmed-article:2464858pubmed:authorsCompleteYlld:pubmed
pubmed-article:2464858pubmed:pagination267-77lld:pubmed
pubmed-article:2464858pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:2464858pubmed:meshHeadingpubmed-meshheading:2464858-...lld:pubmed
pubmed-article:2464858pubmed:meshHeadingpubmed-meshheading:2464858-...lld:pubmed
pubmed-article:2464858pubmed:meshHeadingpubmed-meshheading:2464858-...lld:pubmed
pubmed-article:2464858pubmed:meshHeadingpubmed-meshheading:2464858-...lld:pubmed
pubmed-article:2464858pubmed:meshHeadingpubmed-meshheading:2464858-...lld:pubmed
pubmed-article:2464858pubmed:meshHeadingpubmed-meshheading:2464858-...lld:pubmed
pubmed-article:2464858pubmed:meshHeadingpubmed-meshheading:2464858-...lld:pubmed
pubmed-article:2464858pubmed:meshHeadingpubmed-meshheading:2464858-...lld:pubmed
pubmed-article:2464858pubmed:meshHeadingpubmed-meshheading:2464858-...lld:pubmed
pubmed-article:2464858pubmed:year1988lld:pubmed
pubmed-article:2464858pubmed:articleTitleFour cytotoxic human-human hybridoma antibodies that react with HLA-B27.lld:pubmed
pubmed-article:2464858pubmed:affiliationInstitute of Medical Biology, University of Tromsø School of Medicine, Norway.lld:pubmed
pubmed-article:2464858pubmed:publicationTypeJournal Articlelld:pubmed